Cheng Cheung Ling

This profile gathers the share dealings of Cheng Cheung Ling in Sino Biopharmaceutical Ltd., where the filings describe the role as chief executive. In total, 12 filings cover trades dated from 19 June 2018 to 30 April 2026.

On the open market, the record shows 11 purchases worth €32.8M and 1 sale. No amount is published for 3 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2026: 3 purchases and no sales on the market.

The median purchase comes to €1.8M. As a share of market capitalisation, the median purchase stands at 0.0060%, based on 3 purchases. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 0% of cases; the median change was -6.8%. They describe history only and say nothing certain about the share price ahead.

On 30 April 2026 came the latest disclosure, an open-market purchase for €592k in Sino Biopharmaceutical Ltd. Publication is fast: at least half of the trades appear on HKEX on the same day. This delay matters because a trade only becomes useful information once it is public. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.